Abstract: Compounds of use in therapy and having the formula: ##STR1## in which R.sub.2 and R.sub.3 independently denote H, C.sub.1 -C.sub.4 alkoxy or OH and (A, B)=(oxygen, oxygen) in which case one out of R and R.sub.1 denotes OH, halogen, secondary amino or tertiary amine and the other denotes NHCOR.sub.4, NHNHCOR.sub.5 or NHNHCOCONH.sub.2, or R and R.sub.1 together form .dbd.N--NH--CO--R'.sub.5, .dbd.N--NH--CO--CO--NH.sub.2, (.dbd.N--NH--R.sub.6, .dbd.N--R.sub.7, .dbd.N--O--CO--R.sub.8 or .dbd.C(CH.sub.3)--NH--NH--CO--R.sub.9 ; or (A, B) .dbd.(N--NH--CX--NHR.sub.10, oxygen) in which case R and R.sub.1 together form .dbd.N--OH.

Abstract: Therapeutic compounds having the formula: ##STR1## in which R.sub.2 and R.sub.3 independently denote H, C.sub.1 -C.sub.4 alkoxy or OH and (A, B)=(oxygen, oxygen) in which case one out of R and R.sub.1 denotes OH, halogen, secondary amino or tertiary amine and the other denotes NHNHCONHR.sub.4 or R and R.sub.1 together denote .dbd.N--NH--CX--NHR.sub.5, .dbd.N--NH--CX--N(phenyl).sub.2, .dbd.N--NH--CX--NH--NH--R.sub.5, .dbd.N--NH--C(SCH.sub.3).dbd.N--R.sub.6 or .dbd.N--N.dbd.C(SCH.sub.3)--NH--R.sub.6 ; or (A, B)=(N--OH, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2 ; or (A, B)=(N--NH--CX--NHR.sub.5, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 ; or (A, B)=(N--OH, N--OH) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2.

Abstract: Compounds of formula: ##STR1## in which R represent a cycloalkylmethyl group; ##STR2## group where --A-- symbolizes a hydrocarbon chain and R.sub.1 and R.sub.2 each designate an alkyl group or form jointly with N a heterocyclic radical;an anilinocarbonylmethyl group whose phenyl nucleus is possibly substituted; ora substituted benzyl group.These compounds are useful as drugs having cardiotropic activity.

Abstract: A compound having the formula ##STR1## in which R is hydrogen or alkyl having 1 to 4 carbon atoms; R.sub.1 is hydrogen, alkyl having 1 to 5 carbon atoms, cycloalkylmethyl in which the cycloalkyl group has from 3 to 6 carbon atoms, 2-hydroxyethyl, alkoxycarbonyl in which the alkoxy group has 1 or 2 carbon atoms, 2-carboxypropyl, N-benzyl-2-carbamoyl propyl, phenyl, phenyl substituted by methoxy, trifluoromethyl or acetyl, benzyl, benzyl substituted by halogen, benzoyl, benzoyl substituted by three methoxy groups, 3,5-dimethoxy-4-acetoxy or 3,5-dimethoxy-4-ethoxycarbonyloxy, cinnamoyl, cinnamoyl in which the phenyl ring is substituted with trifluoromethyl or by one or more methoxy groups, phenoxyacetyl, phenoxyacetyl in which the phenyl ring is substituted with halogen or methoxy, and ##STR2## in which m is 2 or 3 and R.sub.2 and R.sub.

Abstract: Compounds having the formula ##STR1## wherein R.sub.1 and R.sub.2 are alkyl having one to 4 carbon atoms, allyl or ##STR2## is pyrrolidino, piperidino, perhydroazepino or morpholino, RX is an inorganic acid, organic acid or an alkyl bromide or iodide, m is 3 or 4, and n is zero or one. The compounds are prepared by (1) reacting benzothienyl-lithium with ##STR3## followed by hydrolysis, or (2) when the substituent is located at the 2 position of the benzothienyl group, by reacting benzothiophene with ##STR4## followed by reaction with ##STR5## The compounds possess bloodplaque aggregation, spasmolytic, analgesic, anti-inflammatory and coronary, cerebral and peripheral vaso-dilatory properties.

Abstract: Compounds having the formula ##STR1## wherein R.sub.1 and R.sub.2 are alkyl having one to 4 carbon atoms, allyl or ##STR2## is pyrrolidino, piperidino, perhydroazepino or morpholino, RX is an inorganic acid, organic acid or an alkyl bromide or iodide, m is 3 or 4, and n is zero or one. The compounds are prepared by (1) reacting benzothienyl-lithium with ##STR3## followed by hydrolysis, or (2) when the substituent is located at the 2 position of the benzothienyl group, by reacting benzothiophene with ##STR4## followed by reaction with ##STR5## The compounds possess blood-plaque aggregation, spasmolytic, analgesic, anti-inflammatory and coronary, cerebral and peripheral vaso-dilatory properties.

Abstract: Compounds having the formula ##STR1## wherein R.sub.1 and R.sub.2 are alkyls or alkenyls having one to 4 atoms or ##STR2## is pyrrolidino, piperidino, perhydroazepino or morpholino, and RX is a salt-forming moiety. The compounds are prepared by reacting 2-acetyl benzothiophene with ##STR3## The compounds possess a blood plaque aggregation inhibiting property and also possess spasmolytic, analgesic, anti-inflammatory and coronary, cerebral and peripheral vasodilatatory properties.